Clinical Trials Logo

Filter by:
NCT ID: NCT05234944 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 1

Pilot Study of Brief Intervention to Support Diabetes Health-Related Quality of Life

T1DALPilot
Start date: December 9, 2022
Phase: N/A
Study type: Interventional

The aims of this pilot study are to evaluate the feasibility, acceptability, preliminary impact, and costs of a brief, behavioral intervention delivered remotely by diabetes educators to people with type 1 diabetes and their family members. The purpose of the intervention is to support health-related quality of life for people with type 1 diabetes of all ages and to support the diabetes health-related quality of life of their parents and partners. This pilot study will explore how this intervention works as a supplement to routine medical care in three clinical care settings: an adult specialty diabetes care setting, a pediatric subspecialty diabetes care setting, and for people who receive diabetes medical care from a primary care provider. To maximize data about feasibility and acceptability of the intervention, all participants in the pilot study will receive the intervention and there will not be randomization to a control condition.

NCT ID: NCT05233761 Active, not recruiting - Insomnia Clinical Trials

Evaluation of an Oral Cannabidiol (CBD)-Terpene Formulation on Sleep Physiology in Participants With Insomnia

Start date: February 18, 2022
Phase: Phase 2
Study type: Interventional

Insomnia is a disorder in which people have inadequate or poor-quality sleep due to a number of factors, such as difficulty falling asleep, waking up frequently during the night with difficulty returning to sleep, waking up too early in the morning, or having unrefreshing sleep. Defined CBD is a capsule composed of highly purified (>99.9%) hemp-derived cannabidiol (CBD) and terpenes produced as a potential sleep aid for people with insomnia. This product contains no detectable Delta-9-tetrahydrocannabinol (Delta-9-THC). This trial is specifically designed to evaluate the efficacy of Defined CBD on sleep physiology in people with insomnia.

NCT ID: NCT05232825 Active, not recruiting - Clinical trials for Relapsing Multiple Sclerosis

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

Ocarina II
Start date: May 3, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).

NCT ID: NCT05232669 Active, not recruiting - Fall Clinical Trials

COcoa Supplement and Multivitamin Outcomes Study: Effects on Falls and Physical Performance

COSMOS
Start date: May 15, 2021
Phase: N/A
Study type: Interventional

The COcoa Supplement and Multivitamin Outcomes Study (COSMOS; NCT02422745) is a randomized clinical trial of cocoa extract supplement (containing a total of 500 mg/d flavanols, including 80 mg. (-)-epicatechins), and a standard multivitamin supplement to reduce the risk of cardiovascular disease and cancer among men aged 60 years and older and women aged 65 years and older. This ancillary study is being conducted among participants in COSMOS and will examine whether the cocoa extract supplement or the multivitamin supplement improve musculoskeletal health and prevent falls and declining physical performance in the increasing number of older adults in the U.S. with potential for clinical and public health benefits.

NCT ID: NCT05232253 Active, not recruiting - Clinical trials for Urinary Bladder, Neurogenic

Cystoealstometer (Bladder Monitor Device)-Home Use

Start date: January 18, 2021
Phase: N/A
Study type: Interventional

The investigators have developed a novel pressure monitoring device called a 'cystoelastometer' that connects to a drainage end ofastandard urinary catheters that are used by patients with a neurogenic bladder on daily clean intermittent catheterization. The device has already been demonstrated to be accurate in measuring bladder pressure compared to the gold standard urodynamics that are performed in the clinic or hospital. This study will assess the patients and care givers ability and experience using the cystoelastometer device in a home setting.

NCT ID: NCT05232071 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 2

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

LEGEND
Start date: June 29, 2022
Phase: Phase 2
Study type: Interventional

The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.

NCT ID: NCT05231954 Active, not recruiting - Clinical trials for Alzheimer Disease and Related Dementias (ADRD)

Digital Detection of Dementia (D Cubed) Studies: D2

Start date: July 5, 2022
Phase: N/A
Study type: Interventional

The specific aim of the pragmatic trial is to evaluate the practical utility and effect of the PDM, the QDRS, and the combined approach (PDM + QDRS) in improving the annual rate of new documented ADRD diagnosis in primary care practices.

NCT ID: NCT05231837 Active, not recruiting - Physical Activity Clinical Trials

Neighborhood Park Youth Sports Program Fee Waiver and Intensive Family Outreach

PARKS
Start date: February 15, 2022
Phase: Phase 3
Study type: Interventional

To evaluate a park-level intervention to increase child moderate/vigorous physical activity (MVPA), and decrease sedentary time among low-income racially/ethnically diverse children ages 6-12 yrs. Neighborhood parks (n=20) from Minneapolis (n=8) and Saint Paul (n=12) park systems will be randomized for a 2-year period to one of two arms: 1) Intensive Park Outreach and Youth Sports Program Fee Waiver (n=10); or 2) Youth Sports Program Fee Waiver Only (n=10). The evaluation cohort will consist of 432 children ages 6-12 yrs who reside in one of the 20 randomized park neighborhoods. Measurements from evaluation cohort-enrolled individual children will be collected at baseline, 6, 12, and 24 months.

NCT ID: NCT05231421 Active, not recruiting - Smoking Cessation Clinical Trials

A Focus Group Study to Explore Smoking Triggers and Acceptability of Just-in-time Adaptive Intervent

Start date: January 18, 2020
Phase:
Study type: Observational

This research intends to identify common smoking triggers and barriers to quitting smoking; understand useful and effective strategies for smoking cessation; and explore the feasibility and acceptability of mobile phone-based interventions among low-income smokers.

NCT ID: NCT05231278 Active, not recruiting - Lung Neoplasms Clinical Trials

Confocal Laser Endomicroscopy Nodule Localization by Robotic Bronchoscopy

CLEAR
Start date: January 20, 2022
Phase: N/A
Study type: Interventional

This study is designed to evaluate the safety and feasibility of real-time needle-based confocal laser endomicroscopy (nCLE) in improving diagnostic accuracy of robotic-assisted bronchoscopy (RANB) biopsy performed with the Monarch® Endoscopy Platform in patients with peripheral pulmonary nodules (PPN).